EMA begins assessment of Pfizer booster application

Pfizer has submitted an application for the Covid-19 vaccine Comirnaty as a booster shot in re-vaccination plans.

The European Medicines Agency's Amsterdam headquarters | Photo: Rob Acket/EMA

The European Medicines Agency (EMA) is analyzing data from Pfizer, which is seeking approval for its Covid-19 vaccine Comirnaty for use as booster dose.

The idea is to use Comirnaty for the re-vaccination of patients aged 16 or older six months after they have received their second dose. The purpose is to restore the protection against Covid-19 before it wanes, the EMA writes on its website.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs